# Search strategy

PubMed	#1	"Dry Eye Syndromes"[Mesh]
1 dolvied	#2	((((((((((((((((((((((((((((((((((((((
	112	Diseases[Title/Abstract])) OR (Dry Eye[Title/Abstract])) OR (Dry Eyes[Title/Abstract])) OR (Evaporative Dry Eye
		Disease[Title/Abstract])) OR (Evaporative Dry Eye Syndrome[Title/Abstract])) OR (Evaporative Dry Eye
	112	Eye[Title/Abstract])) OR (Dry Eye, Evaporative[Title/Abstract])) OR (Evaporative Dry Eyes[Title/Abstract]))
	#3	#1 OR #2
	#4	"Risk Factors"[Mesh]
	#5	((((((((((((((((((((((((((((((((((((((
		Risk)) OR (Risk Factor, Social)) OR (Risk Factors, Social)) OR (Social Risk Factor)) OR (Health Correlates)) OR
		(Correlates, Health)) OR (Population at Risk)) OR (Populations at Risk)) OR (Risk Scores)) OR (Risk Score)) OR
		(Score, Risk)) OR (Risk Factor Scores)) OR (Risk Factor Score)) OR (Score, Risk Factor)
	#6	#4 OR #5
	#7	#3 AND #6
Embase	#1	'dry eye syndromes'/exp OR 'dry eye syndromes'
	#2	'dry eye syndrome':ab,ti OR 'dry eye disease':ab,ti OR 'dry eye diseases':ab,ti OR 'dry eye':ab,ti OR 'dry eyes':ab,ti OR
		'evaporative dry eye disease':ab,ti OR 'evaporative dry eye syndrome':ab,ti OR 'evaporative dry eye':ab,ti OR 'dry eye,
		evaporative':ab,ti OR 'evaporative dry eyes':ab,ti
	#3	#1 OR #2
	#4	'risk factors'/exp OR 'risk factors'
	#5	'factor, risk':ab,ti OR 'risk factor':ab,ti OR 'social risk factors':ab,ti OR 'factor, social risk':ab,ti OR 'factors, social
		risk':ab,ti OR 'risk factor, social':ab,ti OR 'risk factors, social':ab,ti OR 'social risk factor':ab,ti OR 'health
		correlates':ab,ti OR 'correlates, health':ab,ti OR 'population at risk':ab,ti OR 'populations at risk':ab,ti OR 'risk
		scores':ab,ti OR 'risk score':ab,ti OR 'score, risk':ab,ti OR 'risk factor scores':ab,ti OR 'risk factor score':ab,ti OR 'score,
		beered may a are their beere may are beere, their may are their beered may are their beere may are their section,

		risk factor':ab,ti
	#6	#4 OR #5
	#7	#3 AND #6
Web of science	#1	TS=(Dry Eye Syndromes OR Dry Eye Syndrome OR Dry Eye Disease OR Dry Eye Diseases OR Dry Eye OR Dry
		Eyes OR Evaporative Dry Eye Disease OR Evaporative Dry Eye Syndrome OR Evaporative Dry Eye OR Dry Eye,
		Evaporative OR Evaporative Dry Eyes)
	#2	TS=(Risk Factors OR Factor, Risk OR Risk Factor OR Social Risk Factors OR Factor, Social Risk OR Factors, Social
		Risk OR Risk Factor, Social OR Risk Factors, Social OR Social Risk Factor OR Health Correlates OR Correlates,
		Health OR Population at Risk OR Populations at Risk OR Risk Scores OR Risk Score OR Score, Risk OR Risk Factor
		Scores OR Risk Factor Score OR Score, Risk Factor)
Cochrane library	#1	Dry Eye Syndromes
	#2	(Dry Eye Syndromes):ab,ti,kw OR (Dry Eye Syndrome):ab,ti,kw OR (Dry Eye Disease):ab,ti,kw OR (Dry Eye
		Diseases):ab,ti,kw OR (Dry Eye):ab,ti,kw OR (Dry Eyes):ab,ti,kw OR (Evaporative Dry Eye Disease):ab,ti,kw OR
		(Evaporative Dry Eye Syndrome):ab,ti,kw OR (Evaporative Dry Eye):ab,ti,kw OR (Dry Eye, Evaporative):ab,ti,kw
		OR (Evaporative Dry Eyes):ab,ti,kw
	#3	#1 OR #2
	#4	Risk Factors
	#5	(Factor, Risk):ab,ti,kw OR (Risk Factor):ab,ti,kw OR (Social Risk Factors):ab,ti,kw OR (Factor, Social Risk):ab,ti,kw
		OR (Factors, Social Risk):ab,ti,kw OR (Risk Factor, Social):ab,ti,kw OR (Risk Factors, Social):ab,ti,kw OR (Social
		Risk Factor):ab,ti,kw OR (Health Correlates):ab,ti,kw OR (Correlates, Health):ab,ti,kw OR (Population at
		Risk):ab,ti,kw OR (Populations at Risk):ab,ti,kw OR (Risk Scores):ab,ti,kw OR (Risk Score):ab,ti,kw OR (Score,
		Risk):ab,ti,kw OR (Risk Factor Scores):ab,ti,kw OR (Risk Factor Score):ab,ti,kw OR (Score, Risk Factor):ab,ti,kw
	#6	#4 OR #5
	#7	#3 AND #6

The search covered studies published between January 2000 and December 2022.

#### Newcastle-Ottawa Scale adapted for cross-sectional studies

Selection: (Maximum 5 stars)

- 1) Representativeness of the sample:
- a) Truly representative of the average in the target population. \* (all subjects or random sampling)
- b) Somewhat representative of the average in the target population. \* (non-random sampling)
- c) Selected group of users.
- d) No description of the sampling strategy.
- 2) Sample size:
- a) Justified and satisfactory. \*
- b) Not justified.
- 3) Non-respondents:
- a) Comparability between respondents and non-respondents characteristics is established, and the response rate is satisfactory. \*
- b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is unsatisfactory.
- c) No description of the response rate or the characteristics of the responders and the non-responders.
- 4) Ascertainment of the exposure (risk factor):
- a) Validated measurement tool. \*\*
- b) Non-validated measurement tool, but the tool is available or described.\*
- c) No description of the measurement tool.

Comparability: (Maximum 2 stars)

1) The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.

- a) The study controls for the most important factor (select one). \*
- b) The study control for any additional factor. \*


Outcome: (Maximum 3 stars)

- 1) Assessment of the outcome:
- a) Independent blind assessment. \*\*
- b) Record linkage. \*\*
- c) Self report. \*
- d) No description.
- 2) Statistical test:
- a) The statistical test used to analyze the data is clearly described and appropriate, and the measurement of the association is presented, including confidence intervals and the probability level (p value). \*
- b) The statistical test is not appropriate, not described or incomplete.

### Forest Plot of Hispanic Ethnicity

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case control				
Galor et al (2012)	1.66	[1.60, 1.72]	19.2%	220
Test for averal effect Z = 27.4				
cross-sectional				
Schaumberg et al (2003)	1.81	[1.18, 2.79]	15.1%	+
Schaumberg et al (2009)	1.25	[0.93, 1.68]	17.1%	
Fernandez et al(2013)	1.25	[0.59, 2.63]	10.5%	
Farrand et al (2017)	1.34	[1.19, 1.51]	18.9%	<b>正</b> 第
Lee et al(2017)	0.90	[0.89, 0.91]	19.3%	
Total (95% CI)	1.24	[0.93, 1.65]	80.8%	
Hetarogeneity: $Tau^2 = 0.079$ ; Cf. Test for overall effect: $Z = 1.47$			T = 93%	
Total (95% CI)	1.33	[0.93, 1.90]	100.0%	•
Heterogeneity: Tau <sup>2</sup> = 0.174; Ct	n <sup>2</sup> = 1050	143, df = 5 (P < .0	1); i <sup>2</sup> = 100%	
Test for overall effect Z = 1.55	(P= 12)	F		05 1 2
Test for subgroup differences:	$chr^2 = 3.1$	94, df = 1 (P = .05	)	

#### Forest Plot of Menopause.



#### Forest Plot of Alcohol

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
-	0.755.50	0.500,50		I.
case-control				1
Galor et al(2011)	1.49	[1.27, 1.74]	10.6%	
Galor et al (2012)	1.33	[1.32, 1.35]	12.4%	
Yilmaz et al(2015)	1.56	[0.31, 7.88]	0.6%	1 =
Ben-Eli et al (2019)	0.54	[0.33, 0.88]	4.6%	
Total (95% CI)	1.21	[0.94, 1.54]	28.3%	
Haterogenety: Tau = 0.035; Chr =	1501, df	= 3 (P < .01); 1 = 5	036	
Test for overall effect: $Z = 1.50$ (P	(13)			
cross-sectional				1 1 1
Chia et al(2003)	0.70	[0.49, 0.99]	6.8%	
Guo et al (2010)	1.01	[0.75, 1.36]	7.7%	- 100
Ahn et al (2014)	1.10	[0.88, 1.37]	9.3%	
Tan et al (2015)	1.49	[0.55, 4.04]	1.6%	- a
Chung et al (2016)	0.94	[0.64, 1.39]	6.1%	
Gong et al (2017)	1.10	[0.60, 2.01]	3.5%	
Asiedu et al (2017)	1.49	[0.55, 4.04]	1.6%	- im
Ferrero et al (2018)	0.93	[0.35, 2.47]	1.6%	
Kim et al (2019)	0.94	[0.76, 1.17]	9.3%	
Vu et al (2021)	1.09	[0.71, 1.67]	5.5%	_
García-Marqués et al (2022)	1.33	[0.61, 2.91]	2.3%	
Garg et al(2022)	11.67	[6.90, 19.74]	4.3%	-
Total (95% CI)	1.29	[0.91, 1.81]	59.5%	-
telenogeneity Tau <sup>2</sup> = 0.285, Chi <sup>2</sup> =	88.05 df			1
Test for overall effect: Z = 1.44 (P :				
prospective cohort				İ
Magno et al(2021)	1.08	[1.03, 1.12]	12.2%	
Test for overall affect, Z = 3,49 (P)	(10.3			i
Total (95% CI)	1.18	[1.03, 1.35]	100.0%	
Heterogeneity: Tau <sup>2</sup> = 0.038, Chi <sup>2</sup> =	201.70, di		92%	
Test for overall effect, Z = 2,48 (P :				0.2 0.5 1 2 5
Test for subgroup differences: Chi	= 1.76, di	f = 2 (P = .41)		

### Forest Plot of Smoking

Study or	100000	45/2010-001	255150500	Odds Ratio
Subgroup	OR	95% CI	Weight	IV, Random, 95% CI
case-control				
Ben-Eli et al (2019)	0.90	[0.55, 1.47]	2.5%	
Test for overall effect, Z = -0.42 (P	= .87)			
cross-sectional				
Uchino et al (2008)	0.77	[0.53, 1.12]	3.7%	-
Guo et al (2010)	1.06	[0.81, 1.39]	5.3%	
Ahn et al (2014)	0.90	[0.72, 1.13]	6.2%	
Bakkar et al (2016)	1.20	[0.90, 1.60]	5.0%	108
Gong et al (2017)	0.80	[0.43, 1.50]	1.7%	
Lee et al(2017)	1.08	[1.08, 1.08]	10.2%	in
Titiyal et al (2018)	2.14	[1.65, 2.78]	5.5%	
Ferrero et al (2018)	0.73	[0.46, 1.16]	2.8%	
Inomata et al (2019)	1.53	[1.31, 1.79]	7.8%	
Inomata et al (2020)	2.07	[1.49, 2.88]	4.3%	-
Shanti et al (2020)	0.96	[0.65, 1.43]	3.5%	- 10
Tandon et al (2020)	1.20	[1.05, 1.37]	8.4%	Verlan-
Vehof et al (2021)	0.87	[0.80, 0.94]	9.4%	
Chatterjee et al (2021)	1 09	[1.02, 1.16]	9.7%	100
Yang et al (2021)	1.26	[0.82, 1.93]	3.1%	
Khorshed et al (2022)	2.98	[1.58, 5.63]	1.7%	-
García-Marqués et al (2022)	2.20	[0.93, 5.23]	1.0%	
Dossan et al(2022)	1.39	[0.97, 1.99]	3.9%	
Cartes et al(2022)	1.32	[0.94, 1.85]	4.2%	
Total (95% CI)	1.18	[1.08, 1.30]	97.5%	
Heterogeneity Tauf - 0.021; Chif -	118.83	df = 16 (P = .01); f	- 85%	
Test for everall effect Z = 3.61 (P	(10t)			
Total (95% CI)	1.18	[1.07, 1.29]	100.0%	•
Heterogeneity: Tau <sup>2</sup> = 0,021; Chr <sup>2</sup> =			2 - 84%	
Test for overall effect: Z = 3.52 (P			(	0.2 0.5 1 2 5
Test for subgroup differences: Chi		df = 1 (P = 29)		

## Forest Plot of Past Smoking

Study or Subgroup	OR	95% CI	Weight	IV.	10.0	20	Ratio	5% CI	í.
angroup	CAR	33% CI	vergin	1.0	, 140	L	,	<i>I I I I</i>	
cross-sectional									
Lee et al (2002)	1.20	[0.60, 2.40]	3.0%		-	10			
Malet et al (2013)	0.82	[0.54, 1.24]	7.7%		-	0			
Fernandez et al(2013)	1.74	[0.67, 4.54]	1.6%			-	-		
Kim et al (2019)	08.0	[0.57, 1.14]	10.3%		-				
Vehof et al (2021)	1.09	[1.03, 1.15]	56.9%			500			
Total (95% CI)	1.01	[0.85, 1.21]	79.5%			+			
Helerogeneity: Tau <sup>2</sup> = 0.012 Teal for overall affect, Z = (			1); 1 = 28%			50000			
prospective cohort						200			
Moss et al (2000)	1.22	[0.97, 1.53]	20.5%			-			
Test for overall effect. Z = 1	74 (F=	08)							
Total (95% CI)	1.07	[0.94, 1.21]	100.0%						
Heterogeneity: Tau <sup>2</sup> = 0.006	, Chr2 = 8	62, df = 5 (P = .25	5); t <sup>2</sup> = 24%	1		1	M		
Test for overall effect, Z = 1	.06 (P=	29)		0.2	0.5	1	2	5	10
Test for subgroup difference	cs: Chi <sup>2</sup>	1.64, df = 1 (P =	.20)						

## Forest Plot of Current Smoking

Study or	72.2	50000		Odds Ratio
Subgroup	OR	95% CI	Weight	IV, Random, 95% CI
case-control				
Yilmaz et al(2015)	1.43	[0.84, 2.42]	7.2%	
Test for overall effect; Z = 1.3	13 (P = .1	8)		
cross-sectional				
Lee et al (2002)	1.50	[1.01, 2.22]	8.9%	
Chia et al (2003)	0.70	[0.42, 1.16]	7.5%	
Malet et al (2013)	0.80	[0.36, 1.78]	4.6%	
Uchino et al(2013)	0.86	[0.54, 1.36]	8.1%	-
Fernandez et al(2013)	0.32	[0.11, 0.91]	3.2%	-
Chung et al (2016)	0.90	[0.62, 1.30]	9.3%	-
Alshamrani et al (2017)	1.40	[1.06, 1.85]	10.6%	
Kim et al (2019)	0.82	[0.56, 1.20]	9.1%	
Hu et al (2021)	0.76	[0.44, 1.31]	7.0%	
Choi et al (2021)	0.76	[0.34, 1.71]	4.5%	
Wu et al (2021)	1.43	[1.02, 2.00]	9.8%	
Total (95% CI)	0.97	[0.78, 1.20]	82.5%	*
Heterogenesty; Tau <sup>2</sup> = 0.069; ( Test for overall effect: 2 = -0.			H); F = 97%	
prospective cohort				
Moss et al (2000)	1.82	[1.35, 2.45]	10.3%	-
Test for everal effect Z = 3.9	(i × 10 a)	1)		
Total (95% CI)		[0.85, 1.30]	100.0%	-
Heterogenety: Tau <sup>2</sup> = 0.091; ( Test for overall effect: Z = 0.4			n); r = 66%	0.1 0.5 1 2
Test for subgroup differences	s: Chi <sup>2</sup> -	11.88, df = 2 (P <	.01)	

#### Forest Plot of Rosacea or Acne

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case-control				
Galor et al(2011)	1.85	[1.42, 2.41]	16.7%	-
Galor et al (2012)	2.29	[2.25, 2.34]	21.7%	
Yang et al (2015)				1
Total (95% CI)				-
Haterogenety: Tau <sup>2</sup> = 0.0	22. CH <sup>2</sup>	= 4.76, df = 2 (P =	.09), f = 58%	
Test for overall effect. Z				1
cross-sectional				į
Viso et al (2009)	3.49	[1.24, 9.80]	3.9%	8
Roh et al (2016)	1.51	[1.25, 1.83]	18.8%	
Vehof et al (2021)	1.95	[1.28, 2.97]	12.3%	
Alkhaldi et al(2023)	1.51	[1.25, 1.83]	18.8%	
Total (95% CI)	1.59	[1.36, 1.85]	53.7%	•
Heterogeneity: Tau <sup>2</sup> = 0.0	005; Ehr	= 3.63, df = 3 (P =	30); F = 17%	
Test for overall effect Z	= 5.90 (4	H- (61)		
Total (95% CI)	1.96	[1.56, 2.45]	100.0%	-
Heterogeneity: Tau <sup>2</sup> = 0.0		TO SECURE AND ADDRESS.	< .01); t <sup>2</sup> = 85%	
Test for overall effect Z			100000000000000000000000000000000000000	0.2 0.5 1 2 5
Test for subgroup differe	nces: Ch	1 <sup>2</sup> = 8.48. df = 1 (F	P = .01)	

# Forest Plot of Allergic Conjunctivitis

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
cress-sectional				
Vehof et al (2021)	3.82	[3.25, 4.49]	50.8%	STATE OF THE PARTY
Zeleke et al (2022)	5.42	[2.43, 12.09]	11.7%	- III
Ma et al(2022)	5.58	[4.12, 7.55]	37.5%	- 103
Total (95% CI)	4.59	[3.38, 6.23]	100.0%	-
Heterogeneity: Tau = 0	041 Chi	= 5.07, df = 2 (P =	181 F = 61%	
Test for overall effect 2	E = 9.75 (	P< 01)		<u> </u>
Total (95% CI)	4.59	[3.38, 6.23]	100.0%	
			91	
Heterogeneity: Tau <sup>2</sup> = 0.			.08); 1 = 61%	0.5 1 2
Test for overall effect: 2		7.4		
Test for subgroup differ	ences: C	hr - 0.00, df - 0 (P	- NA)	

# Forest Plot of Pterygium

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
cross-sectional				i
Lee et al (2002)	1.90	[1.39, 2.59]	27.7%	
Guo et al (2010)	3.35	[2.58, 4.35]	28.5%	
Viso et al(2011)	1.10	[0.64, 1.91]	22.9%	
Total (95% CI)	1.99	[1.12, 3.55]	79.1%	-
Heterogeneity: Tau <sup>2</sup> = 0.3	222; Chi <sup>2</sup>	= 16.2, df = 2 (P <	:.01); 1 = 88%	
Test for overall effect: Z	= 2.34 (	2 = .02)		
retrospective coho	rt			
Samuel et al(2012)	1.16	[0.61, 2.21]	20.9%	
Test for overall effect. Z	= 0.45 (	2 = .65)		
Total (95% CI)	1.78	[1.05, 3.00]	100.0%	
Heterogeneity: Tau <sup>2</sup> = 0.3	232; Chi <sup>2</sup>	= 20.66, df = 3 (P	< .01); I <sup>2</sup> = 85%	
Test for overall effect: Z	= 2.15 (	P = .03)		0.5 1 2
Test for subgroup differ	ences: Cl	hi <sup>2</sup> = 1.50, df = 1 (	P = .22)	

Forest Plot of Refractive Surgery

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
cross-sectional				i i
Zhang et al (2019)	1.23	[1.15, 1.31]	25.9%	
Yu et al (2019)	1.72	[1.59, 1.87]	25.8%	
Vehof et al (2021)	3.51	[2.99, 4.12]	25.0%	
Alkhaldi et al(2023)	1.79	[1.36, 2.35]	23.2%	
Total (95% CI)	1,90	[1.28, 2.84]	100.0%	-
Helerogeneby: Tau <sup>2</sup> = 0.1 Test for overall affect Z			2 = .01); 1 = 96%	
Total (95% CI)	1.90	[1.28, 2.84]	100.0%	
Heterogenetty: Tau <sup>2</sup> = 0.1	158; Ch <sup>2</sup>	= 157.06, df = 3 (F	9 < .01); f <sup>2</sup> = 98%	
Test for overall effect: Z	= 3.17 (P	< .01)		0.5 1 2
Test for subgroup differe	ences: Ch	$n^2 = 0.00$ , df = 0 (F	2 = NA)	

	F	orest Plot o	of Diabetes	Odds Ratio
Study or Subgroup	OR	95% CI	Weight	IV, Random, 95% C
case-control				i i
Galor et al (2012)	1.06	[1.06, 1.06]	16.8%	
Yang et al (2015)	1.41	[1.03, 1.92]	3.8%	-
Total (95% CI)	1.17	[0.90, 1.52]	20.6%	*
Hetaregenety, Tsu <sup>7</sup> = 0 326; Cr Test for overs# effect: Z = 1.15			7 - 80%	
cross-sectional				i
Chia et al(2003)	1.10	[0.62, 1.96]	1.3%	-
Schaumberg et al (2009)	0.97	[0.75, 1.26]	5.0%	
Viso et al (2009)	1.22	[0.61, 2.44]	0.9%	
Vehof et al(2014)	1.53	[0.99, 2.37]	2.2%	-
Yoon et al(2016)	1.00	[0.86, 1.15]	9.6%	-
Alshamrani et al (2017)	1.51	[1.16, 1.96]	5.0%	100
Gong et al (2017)	1.10	[0.69, 1.76]	1.9%	
Ferrero et al (2018)	0.97	[0.49, 1.91]	1.0%	
Zhang et al (2019)	0.99	[0.91, 1.08]	13.3%	Book .
Inomata et al (2019)	1.39	[0.82, 2.36]	1.6%	-
Kim et al (2019)	1.08	[0.82, 1.41]	4.7%	-
Shanti et al (2020)	1.05	[0.67, 1.64]	2.1%	
Tandon et al (2020)	1.20	[0.98, 1.47]	6.9%	*
Inomata et al(2020)	0.82	[0.42, 1.62]	1.0%	-
Vehof et al (2021)	1.29	[1.14, 1.45]	11.2%	2010
Choi et al (2021)	1.05	[0.59, 1.86]	1.3%	-
Yang et al (2021)	0.96	[0.30, 3.12]	0.3%	
VVu et al (2021)	0.86	[0.59, 1.24]	2.9%	
Khorshed et al (2022)	3.70	[1.42, 9.65]	0.5%	
Dossari et al(2022)	1.35	[0.79, 2.30]	1.5%	-
Garg et al(2022)	1.93	[0.99, 3.77]	1.0%	1
Total (95% CI)	1.14	[1.04, 1.26]	75.3%	•
Helerogensky Teu $^{3}$ = 0.015 C: Test for everal effect: $Z$ = 2.77			$\chi \tilde{\Gamma} = 4.55 h$	
prospective cohort				
Moss et al (2000)	1.38	[1.03, 1.85]	4.1%	-
Test for overall effect: $Z = 2.14$	(P= 83)			
Total (95% CI)	1,14	[1.06, 1.22]	100.0%	
Heterogeneity: $Tau^2 = 0.007$ , Cf Test for overall effect: $Z = 3.68$			), 1 <sup>2</sup> = 49%	0.2 0.5 1 2 5
Test for subgroup differences:	Chi <sup>2</sup> = 1.	43, df = 2 (P = .49	)	

#### Forest Plot of Thyroid Disease

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case-control				i.
Galor et al(2011)	1.48	[0.74, 2.96]	2.7%	
Galor et al (2012)	1.81	[1.79, 1.84]	6.8%	100
Total (95% CB	1.81	[1.78, 1.84]	9.5%	10
Heterogenety, $Tau^2 = 0$ , $CN^2 = 0.32$				
Test for overall effect, Z = 83.95 (P	= 0)			
cross-sectional				1
Wang et al (2012)	1.94	[1.79, 2.10]	6.6%	
Malet et al (2013)	1.18	[0.61, 2.28]	2.9%	-
Vehof et al(2014)	1.61	[1.22, 2.12]	5.5%	100
Paulsen et al (2014)	1.62	[1.20, 2.18]	5.3%	-
Ahn et al (2014)	1.81	[1.45, 2.25]	5.9%	
Yoon et al(2016)	1.05	[1.00, 1.09]	6.7%	
Roh et al (2016)	1.79	[1.41, 2.28]	5.7%	
Roh et al(2016)	1.79	[1.41, 2.28]	5.7%	(100m) (100m)
Alshamrani et al (2017)	1.41	[1.09, 1.83]	5.6%	
Zhang et al (2019)	1.41	[1.27, 1.56]	6.5%	
Yu et al (2019)	1.28	[1.14, 1.45]	6.5%	
Kim et al (2019)	1.44	[0.96, 2.14]	4.5%	-
Wang et al (2021)	5.15	[1.69, 15.72]	1.4%	
Bikbov et al(2022)	1.63	[1.19, 2.24]	5.1%	-883-
Garcia-Marqués et al (2022)	0.35	[0.06, 2.15]	0.6%	-
Dossan et al(2022)	4.53	[1.04, 19.73]	0.9%	-
Garcia-Queiruga et al(2023)	1.50	[1.11, 2.02]	5.3%	- Time-
Alkhaldi et al(2023)	1.42	[0.84, 2.41]	3.6%	-
Total (95% CI)	1.55	[1.32, 1.82]	84.2%	+
Heterogenetty, Tau <sup>2</sup> = 0.086; Cni <sup>2</sup> =	231.65	df = 17 (P < .01); f	93%	
Test for overall effect, Z = 5.26 (P)	.01)			1
prospective cohort				1
Moss et al (2008)	1.73	[1.50, 2.00]	6.3%	100
Test for overall #19ect Z = 7.47 (P		7		
Total (95% CI)	1.57	[1.36, 1.82]	100.0%	
Heterogenety: Tau <sup>2</sup> = 0.083; Chi <sup>2</sup> = Test for overall effect Z = 6.05 (P	594,32,			0.2 0.5 1 2 5

Test for subgroup differences: Chi<sup>2</sup> = 3.89, df = 2 (P = .14)

### Forest Plot of Viral Infection

Galor et al (2012) 1.41 [1.35, 1.47] 41.1%  Yang et al (2016) 3.33 [1.63, 6.78] 3.8%  Total (95% CI) 1.59 [1.22, 2.08] 61.5%  Helerogenery: Tan <sup>2</sup> = 0.034; Chi <sup>2</sup> = 5.82, df = 2 (P = .05); i <sup>2</sup> = 66%  Test for overall effect Z = 3.42 (P < .01)	IV, Random, 95% CI
Galor et al (2011) 1.52 [1.15, 2.00] 16.6%  Galor et al (2012) 1.41 [1.35, 1.47] 41.1%  Yang et al (2015) 3.33 [1.63, 6.78] 3.8%  Total (95% CI) 1.59 [1.22, 2.08] 61.5%  Haterogeneity: Tail = 0.034; Chi = 5.82, df = 2 (P = .05); f = 66%  Test for overall effect Z = 3.42 (P < .01)	
Galor et al (2012) 1.41 [1.35, 1.47] 41.1%  Yang et al (2016) 3.33 [1.63, 6.78] 3.8%  Total (95% CI) 1.59 [1.22, 2.08] 61.5%  Haterogenery: Tan <sup>2</sup> = 0.034; Chi <sup>2</sup> = 5.82, df = 2 (P = .05); i <sup>2</sup> = 66%  Test for overall effect Z = 3.42 (P < .01)	
Yang et al (2015) 3.33 [1.63, 6.78] 3.8%  Total (95% CI) 1.59 [1.22, 2.08] 61.5%  Heterogenery: Tair = 0.034; Chr = 5.82, dt = 2 (P = .05); r = 66%  Test for overall effect Z = 3.42 (P < .01)	-83-
Total (95% CI) 1.59 [1.22, 2.08] 61.5%  Haterogenery: Tair = 0.034; Chr = 5.82, dr = 2 (P = .05); r = 66%  Test for overall effect Z = 3.42 (P < .01)  cross-sectional	
Haterogeneity: $T_{BH}^2 = 0.034$ ; $C_{BI}^2 = 5.82$ , $dI = 2.(P = .05)$ ; $I^2 = 66\%$ Test for overall effect $Z = 3.42$ (P < .01) <b>cross-sectional</b>	1
Helerogenery: $T_{BH}^2 = 0.034$ ; $C_{BH}^2 = 5.82$ , $df = 2.(P = .05)$ ; $f^2 = 66\%$ . Test for overall effect $Z = 3.42$ (P < .01) cross sectional Wang et al (2012) 1.64 [1.49, 1.81] 35.8%	-
cross sectional	
Wang et al (2012) 1.64 [1.49, 1.81] 35.8%	į
Vehofetal (2021) 0.96 [0.41, 2.25] 2.7%	-
Total (95% CI) 1.49 [1.00, 2.23] 38.5%	
Helerogenetly, $Tau^2 = 0.048$ , $Cht^2 = 1.5$ , $dt = 1$ (P = .22), $t^2 = 33\%$	
Test for overall effect, Z = 1.97 (P = .05)	
Total (95% CI) 1.54 [1.33, 1.78] 100.0%	
Heterogeneity: Tau <sup>2</sup> = 0.013; Chi <sup>2</sup> = 14.05, df = 4 (P < .01); f <sup>2</sup> = 72%	1 1 1 1
Test for overall effect: Z = 5.86 (P < .01)	0.2 0.5 1 2
Test for subgroup differences; $Ch^2 = 0.07$ , $df = 1 (P = .79)$	

#### Forest Plot of Betablockers

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case control				
Galor et al (2012)	1.65	[1.64, 1.66]	31.6%	901
Chen et al(2015)				100
Total (95% CI)				13
Heterogenety: Tau <sup>2</sup> - U;	chi? - 0.4	1. qt - 1  F - 52	2 - 67%	1
Test for overall effect. Z				
cross-sectional				1
Malet et al (2013)	0.90	[0.63, 1.29]	14.4%	-10-
Ferrero et al (2018)	1.59	[1.07, 2.36]	13.0%	- 100
Total (95% CI)	1.19	[0.68, 2.08]	27.5%	
Reterogenety, Test <sup>2</sup> = 0.1	75 Ch <sup>2</sup> -	4.55, dF = 1 (F =	$04), \tilde{r} = 77\%$	
Test for overall effect Z	= 0.61 (P	= .54)		
prospective cohort				1
Wolpert et al (2021)	1 02	[0.72, 1.45]	14.9%	-68
Test for overall effect. Z	= 0.11 (2	= 91)		1
Total (95% CI)	1.38	[1.15, 1.67]	100.0%	
Heterogenety: Tau <sup>2</sup> = 0.0	29; Chf =	= 18.36, df = 4 (P <	: .01); i <sup>2</sup> = 78%	
Test for overall effect: Z				0.2 0.5 1 2
Test for subgroup differe	nces: Ch	i <sup>2</sup> = 8.50, df = 2 (P	= .01)	

#### Forest Plot of Diuretics

Study or Subgroup	OR	9	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case control					1
Galor et al (2012)	1.75	[1.74.	1.77	13.8%	S CONTROL OF THE PARTY OF THE P
Test for overall effect: Z =	1000000		1.711	13.070	
TOST HOT TIPE HIS BUTTON L. C.	127,000 ()	-0)			1
cross-sectional					
Malet et al (2013)	1.27	[0.86]	1.871	10.7%	- 300
Ofaniyan et al (2016)	12.33	[1.32, 1	15.33]	1.3%	1
Ferrero et al (2018)	1.69	[1.07]	2.681	9.7%	
Zhang et al (2019)	1.13	[1.01	1.27	13.5%	
Yu et al (2019)	1.23	11.06	1.431	13.3%	
Total (95% CI)	1.25	1.06	1.46]	48.4%	4
fielesogenely: Tau <sup>2</sup> = 0.01	3, Chi <sup>2</sup> = 7	52 df = 4 (	P= (f)	= 47%	1
Test for overall effect: Z =	2.70 (P c	B†)			1
prespective cohort					
Moss et al(2004)	1.38	[1.02]	1.86]	11.7%	- Paris
Moss et al (2008)	1.26	10.99	1.61]	12.4%	ando Cores
Wolpert et al (2021)	0.90	[0.82]	0.99]	13.6%	ED)
Total (95% CI)	1.13	0.84	1.523	37.7%	
fleterogenety: Tau <sup>2</sup> = 0.05	$\delta_i$ $Ch^2 = 1$	2.17, df = 2	(P = 01)	$t^2 = 84\%$	T
Test for overalt effect: Z =	0.83 (P =	41)			1
Total (95% CI)	1.33	[1.02.	1.73]	100.0%	
Heterogeneity: Tau <sup>2</sup> = 0.13	1; Chr = 2			); I <sup>2</sup> = 97%	
Test for overall effect. Z =				·	0.5 1 2
Test for subgroup differen	res Chr -	25.72 dt -	2/P < 0	1)	

# Forest Plot of Multivitamins

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case-control	252225			_
Yang et al (2015) Test for overall effect. Z =		[0.53, 0.97]	32.4%	
cross-sectional				
Paulsen et al (2014)	1.03	[0.77, 1.37]	33.1%	-
Test for overall effect: Z =	= 0.20 (P	= .84)		
prospective cohort				
Moss et al (2000)	1.41	[1.09, 1.82]	34.5%	
Test for overall effect: Z =	= 2.63 (P	< .01)		
Total (95% CI)	1.02	[0.69, 1.50]	100.0%	
Heterogeneity: Tau <sup>2</sup> = 0.09	95; Chi <sup>2</sup> =	11.14, df = 2 (P <	.01); I <sup>2</sup> = 82%	
Test for overall effect: Z =	= 0.10 (P	= .92)		0.2 0.5 1 2 5
Test for subgroup differen	nces: Chi	2 = 11.14, df = 2 (F	2 < .01)	

### Forest Plot of Oral Contraceptives

Study or Subgroup	OR	Weight	Odds Ratio IV, Random, 95% CI	
cross-sectional			5755	
Asiedu et al (2017)	4.04	[1.02, 16.00]	3.9%	
Wang et al (2021)	2.58		13.3%	
García-Marqués et al (2022)		THE RELEASE WHEN THE PARTY STATES	1.6%	i
Total (95% CI)	2.77	[1.48, 5.18]	18,8%	
Heterogeneity: Teu <sup>2</sup> = 0; CHI <sup>2</sup> = 0.41 Test for overall effect; Z = 3.20 (P) retrospective cohort		p = .02), 1 = 0%		
He et al (2022)	2.79	[2.07, 3.77]	81.2%	mba .
Test for overall affect, Z = 6.85 (F)	- energy			
Total (95% CI)	2.79	[2.13, 3.65]	100.0%	
Heterogeneity: Teu <sup>2</sup> - 0; Chi <sup>2</sup> - 0.41	df - 3 (	P = .94); P = 0%		
Test for overall effect: Z = 7.42 (P	< .01)			0.2 0.5 1 2 5
Test for subgroup differences: Chi	= 0.00.	df = 1 (P = .99)		

Study or						dds Ratio	
Subgroup	OR	3	95% CI	Weight	IV, Ra	andom, 95% (	1
ase-control						1	
an der Vaart et al(2015)	2.80	[2.61,	3.01]	32.8%			
(ilmaz et al(2015)	2.66	[1.67,	4.23]	27.7%		-	
Total (95% CI)	2.80	[2.61.	3.00]	60.5%			
laterogeneity: Tau <sup>2</sup> - 0; Chi <sup>2</sup> - 0.05	df-1 (P	- 83); l <sup>2</sup> +1	0%			1	
est for overall effect; Z = 28.50 (P	< .01)					1	
ross-sectional						i	
/ehof et al (2021)	1.26	[1.11,	1.44]	32.5%			
Garcia-Marqués et al (2022)	14.31	[1.83, 1	11.73]	7.0%		1	- 100
otal (95% CI)	3,39	[0.33,	35.20]	39.5%	1.0		
electrogeneity: $Tau^{T} = 2.401$ , $Ch^{T} = 881$ for overall effect $Z = 1.02$ (P =		1 (P = .02);	1 = 81%				
otal (95% CI)	2.39	[1.30,	4.39]	100.0%		-	
leterogeneity: Tau2 = 0.294; Ch2 =	112.99, df	= 3 (P < .0	1); = 97	%	0.2 0.5	1 1 1	2

### Forest Plot of Depression

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% Cl
*	3405457		D.C.S.O.	
case-control				3-
Galor et al(2011)	1.91	[1.73, 2.10]	6.7%	
Galor et al (2012)	1.34	[1.33, 1.35]	6.8%	110
Hallak et al(2015)	2.86	[1.04, 7.87]	2.3%	
van der Vaart et al(2015)	2.90	[2.71, 3.11]	6.8%	
Yilmaz et al(2015)	2.06	[1.30, 3.27]	4.8%	
Total (95% CI)	2.02	[1.47, 2.78]	27.4%	**
Haterogeneity. Tau $^{2}$ = 0.103; $\text{Chi}^{2}$ =	528.18,	$df = 4 (P = .01)/1^2 =$	99%	1
Test for overall effect, $Z = 4.33$ (P	(.01)			
cross-sectional				
Wang et al (2012)	211	[1.93, 2.31]	6.7%	
Fernandez et al(2013)	1.16	[0.46, 2.91]	2.6%	
Vehof et al(2014)	1.67	[1.27, 2.19]	6.0%	
Yoon et al(2016)	1.07	[1.03, 1.12]	6.8%	
Ferrero et al (2018)	1.40	[0.82, 2.40]	4.4%	
Inomata et al (2019)	1.68	[1.23, 2.29]	5.8%	-68-
Kim et al (2019)	1.21	[0.97, 1.52]	6.2%	
Inomata et al (2020)	7.39	[3.70, 14.78]	3.5%	
Inomata et al(2020)	0.90	[0.62, 1.31]	5.4%	
Vehof et al (2021)	1.52	[1.42, 1.62]	6.8%	
García-Marquès et al (2022)	1.88	[0.22, 15.82]	0.7%	
An et al (2022)	1.37	[1.06, 1.77]	6.1%	
Bikbov et al(2022)	1.04	[1.01, 1.07]	6.8%	
Cartes et al(2022)	1.57	[0.99, 2.48]	4 8%	-
Total (95% CI)	1.48	255 CONT (455 LANS)	72.6%	-
Heterogeneity Tau = 0.126 Chr =	547.86		96%	
Test for everall effect $Z = 3.60$ (P	(10)			
Total (95% CI)	1.62	[1.34, 1.95]	100.0%	
Heterogeneity Tau <sup>2</sup> = 0 134; Chi <sup>2</sup> =			7.707 7.707	
Test for overall effect: Z = 5.04 (P			W. House,	0.2 0.5 1 2 5
Test for subgroup differences: Chi		15 1 15 11		


## Forest Plot of Post-Traumatic Stress Disorder (PTSD)

Study or Subgroup	OR	95% CI	Weight	Odds Ratio IV, Random, 95% CI
case-control				I.
Galor et al (2012)	1.43	[1.42, 1.45]	99.8%	III.
Yang et al (2015)		[1.04, 2.01]		
Total (95% CI)	1.43	[1.42, 1.45]	99.9%	
Haterpoonaty: Tau <sup>2</sup> - 0; Ch	-0.01,	dr + 1 (P - 94); P -	096	
Test for everall effect: $Z \sim 0$	37.10 m-	0)		1
cross-sectional				
Femandez et al(2013)	4.08	[1.10, 15.14]	0.0%	-
Vehof et al (2021)	1.23	[0.79, 1.91]	0.1%	
Total (95% CI)	1.90	[0.61, 5.87]	0.1%	
Heterogenety Tau = 0.470	$Ch^2 = 2$	89; df = 1 (P = .09)	12 = 86%	į
Test for overall effect. Z = 1	.11 (P=.	27)		1
Total (95% CI)	1.43	[1.42, 1.45]	100.0%	
Heterogenety: Tau <sup>2</sup> = 0. Chi		A THIRD VIEW TO COLUMN		
Test for overall effect: Z = 0			143,956	0.2 0.5 1 2 5
Test for subgroup difference	es Chi <sup>2</sup>	0.24 df = 1 (P = E	32)	


#### Forest Plot of Stress


Study or						Odds Rat	io
Subgroup	OR	95%	% CI	Weight	IV, I	Random,	95% CI
case-control						1	
Yilmaz et al(2015)	2.33	[1.48, 3	.67]	15.2%		-	
Talens-Estarelles et al (2022)	2.37	[1.06, 5	29]	7.5%		18	
Total (95% CI)	2.34	[1.58, 3	(47)	22.7%		-	
Helerogeneity $Tau^2 = 0$ , $Chi^2 = 0$ , $dF =$	15=1	97) F = 0%				1	
Text for overall effect: $Z = 4.22$ (R <	01)					1	
cross-sectional						1	
Chung et al (2016)	1.33	[1.05, 1	69]	23.4%			
Hyon et al (2019)	1.17	[1.03, 1	.32]	27.6%		EZ	
Garcia-Marqués et al (2022)	4.31	[0.87, 21	.25]	2.3%			
An et al (2022)	1.71	[1.37, 2	14]	24.1%			
Total (95% CI)	1.41	[1.10, 1	.79]	77.3%		-	
Heterogenopy: Tau <sup>3</sup> = 0.037; Chi <sup>4</sup> = 10		3 P~ 015	- 723	5		1	
Test for overall effect Z = 2.75 (P x )	011					1	
Total (95% CI)	1.59	[1.24, 2	.05]	100.0%		•	
Heterogeneity: $Tau^2 = 0.057$ ; $Chi^2 = 16$ Test for overall effect $Z = 3.60$ (P <		5 (P < .01);	7 - 749	6	0.2 0.5	1 2	5
Test for subgroup differences: Chi <sup>3</sup> -	A 65 44	-1/P - nas	3				


# Funnel Plot of Hispanic Ethnicity




# Funnel Plot of Menopause










# Funnel Plot of Smoking




# Funnel Plot of Past Smoking










# Funnel Plot of Allergic Conjunctivitis


















### Funnel Plot of Viral Infection





### Funnel Plot of Betablockers

























### Funnel Plot of Depression



## Funnel Plot of Post-Traumatic Stress Disorder (PTSD)





# Sensitivity Analysis of Hispanic Ethnicity

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al (2012)	1.24 [0.93, 1.65]	
Omitting Schaumberg et al (2003)		
Omitting Schaumberg et al (2009)		
Omitting Fernandez et al(2013)	1.34 [0.91, 1.96]	
Omitting Farrand et al (2017)	1.33 [0.88, 1.99]	
Omitting Lee et al(2017)	1.47 [1.25, 1.73]	
Total (95% CI)	1.33 [0.93, 1.90]	
		0.75 1 1.5

## Sensitivity Analysis of Menopause

Study	Odds Ratio IV, Random, 95% CI	ľ		ds Ra dom,	95% C	CI
Omitting Olaniyan et al (2016)	1.21 [0.84, 1.75]			-	-	
Omitting Choi et al (2020)	2.30 [0.90, 5.84]			253		
Omitting Wang et al (2021)	2.19 [0.69, 6.90]		- 23	3		
Omitting García-Marqués et al (2022)	1.31 [0.75, 2.27]					
Total (95% CI)	1.52 [0.84, 2.74]	15.5				
是全年 2000年 100日 CREET 100 100 III	Harolina School Harbin	33	1	3).		1
		0.2	0.5	1	2	5

## Sensitivity Analysis of Alcohol

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al(2011)	1.15 [1.00, 1.33]	
Omitting Galor et al (2012)	1.19 [0.97, 1.46]	
Omitting Yilmaz et al(2015)	1.18 [1.03, 1.35]	
Omitting Ben-Eli et al (2019)	1.23 [1.07, 1.40]	
Omitting Chia et al(2003)	1.23 [1.07, 1.41]	-
Omitting Guo et al (2010)	1.20 [1.04, 1.38]	
Omitting Ahn et al (2014)	1.19 [1.03, 1.37]	2
Omitting Tan et al (2015)	1.18 [1.03, 1.35]	
Omitting Chung et al (2016)	1.20 [1.05, 1.38]	
Omitting Gong et al (2017)	1.19 [1.03, 1.36]	
Omitting Asiedu et al (2017)	1.18 [1.03, 1.35]	-
Omitting Ferrero et al (2018)	1.19 [1.04, 1.36]	
Omitting Kim et al (2019)	1.21 [1.05, 1.39]	
Omitting Wu et al (2021)	1.19 [1.04, 1.36]	
Omitting García-Marqués et al (2022)	1.18 [1.03, 1.35]	
Omitting Garg et al(2022)	1.08 [0.96, 1.22]	
Omitting Magno et al(2021)	1.22 [1.00, 1.48]	
Total (95% CI)	1.18 [1.03, 1.35]	
		0.8 1 1.25

### Sensitivity Analysis of Smoking

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Ben-Eli et al (2019)	1.18 [1.08, 1.30]	
Omitting Uchino et al (2008)	1.20 [1.09, 1.31]	
Omitting Guo et al (2010)	1.18 [1.08, 1.30]	- 100
Omitting Ahn et al (2014)	1.20 [1.09, 1.32]	
Omitting Bakkar et al (2016)	1.18 [1.07, 1.29]	
Omitting Gong et al (2017)	1.18 [1.08, 1.30]	in the second
Omitting Lee et al(2017)	1.20 [1.05, 1.37]	
Omitting Titiyal et al (2018)	1.13 [1.04, 1.23]	
Omitting Ferrero et al (2018)	1.19 [1.09, 1.31]	
Omitting Inomata et al (2019)	1.15 [1.05, 1.26]	
Omitting Inomata et al (2020)	1.14 [1.05, 1.25]	
Omitting Shanti et al (2020)	1.19 [1.08, 1.30]	
Omitting Tandon et al (2020)	1.18 [1.07, 1.30]	
Omitting Vehof et al (2021)	1.21 [1.10, 1.33]	
Omitting Chatterjee et al (2021)	1.19 [1.07, 1.33]	
Omitting Yang et al (2021)	1.17 [1.07, 1.29]	
Omitting Khorshed et al (2022)	1.16 [1.06, 1.26]	
Omitting García-Marqués et al (2022)		
Omitting Dossari et al(2022)	1.17 [1.07, 1.28]	
Omitting Cartes et al(2022)	1.17 [1.07, 1.28]	
Total (95% CI)	1.18 [1.07, 1.29]	
		0.8 1 1.25

## Sensitivity Analysis of Past Smoking

Study	Odds Ratio IV, Random, 95% CI	IV,	Odds Ratio Random, 95% CI	
Omitting Lee et al (2002)	1.06 [0.91, 1.22]			
Omitting Malet et al (2013)	1.09 [0.98, 1.22]			
Omitting Fernandez et al(2013)				
Omitting Kim et al (2019)	1.09 [1.04, 1.15]			
Omitting Vehof et al (2021)	1.03 [0.81, 1.31]	-		
Omitting Moss et al (2000)	1.01 [0.85, 1.21]			
Total (95% CI)	1.07 [0.94, 1.21]	Ī.		ī
		0.8	1 1	.25

# Sensitivity Analysis of Current Smoking

Study	Odds Ratio IV, Random, 95% CI		Odds Ratio andom, 95% Cl
Omitting Yilmaz et al(2015)	1.02 [0.81, 1.28]	-	
Omitting Lee et al (2002)	1.01 [0.80, 1.27]	-	
Omitting Chia et al(2003)	1.09 [0.88, 1.35]		
Omitting Malet et al (2013)	1.06 [0.85, 1.32]		
Omitting Uchino et al(2013)	1.07 [0.85, 1.34]		
Omitting Fernandez et al(2013)	1.10 [0.90, 1.34]		<del></del>
Omitting Chung et al (2016)	1.06 [0.85, 1.34]		
Omitting Alshamrani et al (2017)		-	
Omitting Kim et al (2019)	1.08 [0.86, 1.35]	-	
Omitting Hu et al (2021)	1.08 [0.86, 1.34]		
Omitting Choi et al (2021)	1.07 [0.86, 1.33]	-	
Omitting Wu et al (2021)	1.01 [0.80, 1.28]		
Omitting Moss et al (2000)	1.00 [0.82, 1.22]		
Total (95% CI)	1.05 [0.85, 1.30]	-	
		0.8	1 1.25

## Sensitivity Analysis of Rosacea or Acne

Study	Odds Ratio IV, Random, 95% CI		Odds Ratio Random, 95	The second second
Omitting Galor et al(2011)	1.99 [1.53, 2.59]			
Omitting Galor et al (2012)	1.80 [1.48, 2.20]			
Omitting Yang et al (2015)	1.85 [1.47, 2.34]			
Omitting Viso et al (2009)	1.91 [1.52, 2.41]			
Omitting Roh et al (2016)	2.06 [1.64, 2.60]			
Omitting Vehof et al (2021)	1.97 [1.53, 2.52]			
Omitting Alkhaldi et al(2023)	2.06 [1.64, 2.60]			
Total (95% CI)	1.96 [1.56, 2.45]		23	-
		0.5	1	2

## Sensitivity Analysis of Allergic Conjunctivitis

Study	Odds Ratio IV, Random, 95% CI	ľ	Odds Ratio IV, Random, 95% C		CI	
Omitting Vehof et al (2021) Omitting Zeleke et al (2022)						
Omitting Ma et al(2022)	3.87 [3.30, 4.54]					
Total (95% CI)	4.59 [3.38, 6.23]	Г	-1	4	1	-
		0.2	0.5	1	2	5

# Sensitivity Analysis of Pterygium

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Lee et al (2002)	1.68 [0.72, 3.89]	
Omitting Guo et al (2010)	1.44 [0.97, 2.13]	4-1-
Omitting Viso et al(2011)	2.07 [1.20, 3.57]	
Omitting Samuel et al(2012)	1.99 [1.12, 3.55]	
Total (95% CI)	1.78 [1.05, 3.00]	
		3. St. 53
		0.5 1 2

# Sensitivity Analysis of Refractive Surgery

Study	Odds Ratio IV, Random, 95% CI	
Omitting Zhang et al (2019) Omitting Yu et al (2019)	2.22 [1.35, 3.65] 1.97 [0.95, 4.12]	
Omitting Vehof et al (2021) Omitting Alkhaldi et al(2023)	1.54 [1.17, 2.03] 1.94 [1.21, 3.11]	
Total (95% CI)	1.90 [1.28, 2.84]	05 1 2

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al (2012)	1.17 [1.07, 1.28]	
Omitting Yang et al (2015)	1.13 [1.05, 1.21]	
Omitting Chia et al(2003)	1.14[1.06, 1.22]	- 10
Omitting Schaumberg et al (2009)	1.15 [1.07, 1.24]	-
Omitting Viso et al (2009)	1.14 [1.06, 1.22]	- 8
Omitting Vehof et al(2014)	1.13 [1.05, 1.21]	一章
Omitting Yoon et al(2016)	1.16 [1.07, 1.25]	
Omitting Alshamrani et al (2017)	1.12 [1.05, 1.19]	
Omitting Gong et al (2017)	1.14[1.06, 1.22]	
Omitting Ferrero et al (2018)	1.14 [1.06, 1.22]	-
Omitting Zhang et al (2019)	1.17 [1.08, 1.27]	
Omitting Inomata et al (2019)	1.14 [1.06, 1.22]	-
Omitting Kim et al (2019)	1.14 [1.06, 1.23]	-
Omitting Shanti et al (2020)	1.14[1.06, 1.23]	(E)
Omitting Tandon et al (2020)	1.14 [1.06, 1.22]	-
Omitting Inomata et ai(2020)	1.14 [1.07, 1.23]	- 8
Omitting Vehof et al (2021)	1.11 [1.04, 1.19]	- 100
Omitting Choi et al (2021)	1.14 [1.06, 1.22]	- 101
Omitting Yang et al (2021)	1.14[1.06, 1.22]	100
Omitting Wu et al (2021)	1.15 [1.07, 1.23]	
Omitting Khorshed et al (2022)	1.13 [1.06, 1.20]	100
Omitting Dossari et al(2022)	1.14 [1.06, 1.22]	一事
Omitting Garg et al(2022)	1.13 [1.06, 1.21]	
Omitting Moss et al (2000)	1.13 [1.05, 1.21]	
Total (95% CI)	1.14 [1.06, 1.22]	

Sensitivity Analysis of Thyroid Disease

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al(2011)	1.58 [1.36, 1.83]	
Omitting Galor et al (2012)	1.56 [1.34, 1.81]	
Omitting Wang et al (2012)	1.55 [1.32, 1.82]	
Omitting Malet et al (2013)	1.59 [1.37, 1.84]	
Omitting Vehof et al(2014)	1.57 [1.35, 1.83]	
Omitting Paulsen et al (2014)	1.57 [1.35, 1.83]	
Omitting Ahn et al (2014)	1.56 [1.34, 1.82]	
Omitting Yoon et al(2016)	1.63 [1.50, 1.77]	
Omitting Roh et al (2016)	1.56 [1.34, 1.82]	-
Omitting Roh et al(2016)	1.56 [1.34, 1.82]	
Omitting Alshamrani et al (2017)	1.58 [1.36, 1.84]	
Omitting Zhang et al (2019)	1.59 [1.36, 1.85]	No. of the last of
Omitting Yu et al (2019)	1.59 [1.37, 1.86]	-
Omitting Kim et al (2019)	1.58 [1.36, 1.84]	-
Omitting Wang et al (2021)	1.55 [1.33, 1.79]	
Omitting Bikbov et al(2022)	1.57 [1.35, 1.83]	
Omitting Garda-Marqués et al (2022)		
Omitting Dossari et al(2022)	1.56 [1.34, 1.81]	
Omitting Garcia-Queiruga et al(2023)	1.58 [1.36, 1.83]	-
Omitting Alkhaldi et al(2023)	1.58 [1.36, 1.83]	
Omitting Moss et al (2008)	1.56 [1.34, 1.82]	
Total (95% CI)	1.57 [1.36, 1.82]	
		0.75 1 1.5

Sensitivity Analysis of Thyroid Disease

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al(2011)	1.58 [1.36, 1.83]	
Omitting Galor et al (2012)	1.56 [1.34, 1.81]	
Omitting Wang et al (2012)	1.55 [1.32, 1.82]	
Omitting Malet et al (2013)	1.59 [1.37, 1.84]	
Omitting Vehof et al(2014)	1.57 [1.35, 1.83]	
Omitting Paulsen et al (2014)	1.57 [1.35, 1.83]	
Omitting Ahn et al (2014)	1.56 [1.34, 1.82]	
Omitting Yoon et al(2016)	1.63 [1.50, 1.77]	
Omitting Roh et al (2016)	1.56 [1.34, 1.82]	-
Omitting Roh et al(2016)	1.56 [1.34, 1.82]	
Omitting Alshamrani et al (2017)	1.58 [1.36, 1.84]	
Omitting Zhang et al (2019)	1.59 [1.36, 1.85]	No. of the last of
Omitting Yu et al (2019)	1.59 [1.37, 1.86]	-
Omitting Kim et al (2019)	1.58 [1.36, 1.84]	-
Omitting Wang et al (2021)	1.55 [1.33, 1.79]	
Omitting Bikbov et al(2022)	1.57 [1.35, 1.83]	
Omitting Garda-Marqués et al (2022)		
Omitting Dossari et al(2022)	1.56 [1.34, 1.81]	
Omitting Garcia-Queiruga et al(2023)	1.58 [1.36, 1.83]	-
Omitting Alkhaldi et al(2023)	1.58 [1.36, 1.83]	
Omitting Moss et al (2008)	1.56 [1.34, 1.82]	
Total (95% CI)	1.57 [1.36, 1.82]	
		0.75 1 1.5

## Sensitivity Analysis of Betablockers

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al (2012)	1.25 [0.93, 1.68]	
Omitting Chen et al(2015)	1.27 [0.92, 1.77]	
Omitting Malet et al (2013)	1.53 [1.33, 1.76]	
Omitting Ferrero et al (2018)	TO A COMPANY OF THE PROPERTY O	
Omitting Wolpert et al (2021)		
Total (95% CI)	1.38 [1.15, 1.67]	
		0.75 1 1.5

## Sensitivity Analysis of Diuretics

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI	
Omitting Galor et al (2012)	1.20 [1.03, 1.41]		
Omitting Malet et al (2013)	1.33 [1.01, 1.77]		
Omitting Olaniyan et al (2016)	1.29 [0.99, 1.68]		
Omitting Ferrero et al (2018)	1.29 [0.98, 1.71]		
Omitting Zhang et al (2019)	1.36 [1.01, 1.84]		
Omitting Yu et al (2019)	1.35 [1.00, 1.81]		
Omitting Moss et al(2004)	1.32 [0.99, 1.76]		
Omitting Moss et al (2008)	1.34 [1.00, 1.78]		
Omitting Wolpert et al (2021)	1.39 [1.12, 1.72]		
Total (95% CI)	1.33 [1.02, 1.73]		
		0.75 1 1.5	

## Sensitivity Analysis of Multivitamins

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Yang et al (2015)	1.21 [0.89, 1.65]	
Omitting Paulsen et al (2014)	THE RESIDENCE AND ADDRESS OF THE PROPERTY OF T	
Omitting Moss et al (2000)	0.86 [0.60, 1.23]	
Total (95% CI)	1.02 [0.69, 1.50]	
		0.75 1 1.5

## Sensitivity Analysis of Oral Contraceptives

Study	Odds Ratio IV, Random, 95% (	CI		lds Ra idom,	itio 95% CI	
Omitting Asiedu et al (2017)	2.75 [2.08, 3.62]				-	5
Omitting Wang et al (2021)	2.82 [2.11, 3.77]					
Omitting García-Marqués et al (2022)						-
Omitting He et al (2022)	2.77 [1.48, 5.18]					
Total (95% CI)	2.79 [2.13, 3.65]				-	
			3	3	1	
		0.2	0.5	1	2	

## Sensitivity Analysis of Anxiety

Study	Odds Ratio IV, Random, 95% (	CI	itio 95% CI			
Omitting van der Vaart et al(2015)	2.28 [1.02, 5.10]					_
Omitting Yilmaz et al(2015)	2.32 [1.10, 4.89]			-		
Omitting Vehof et al (2021)	2.82 [2.29, 3.49]					
Omitting García-Marqués et al (2022)	2.09 [1.11, 3.91]			-		
Total (95% CI)	2.39 [1.30, 4.39]					- Description
		3	3).	3	4	3
		0.2	0.5	1	2	5

### Sensitivity Analysis of Depression

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% CI
Omitting Galor et al(2011)	1.60 [1.31, 1.96]	
Omitting Galor et al (2012)	1.64 [1.35, 2.01]	
Omitting Hallak et al(2015)	1.60 [1.32, 1.93]	
Omitting van der Vaart et al(2015)	1.54 [1.30, 1.83]	
Omitting Yilmaz et al(2015)	1.60 [1.32, 1.95]	
Omitting Wang et al (2012)	1.59 [1.31, 1.94]	
Omitting Fernandez et al(2013)	1.64 [1.35, 1.98]	
Omitting Vehof et al(2014)	1.62 [1.32, 1.98]	
Omitting Yoon et al(2016)	1.67 [1.38, 2.02]	
Omitting Ferrero et al (2018)	1.63 [1.34, 1.99]	
Omitting Inomata et al (2019)	1.62 [1.32, 1.98]	- in-
Omitting Kim et al (2019)	1.65 [1.36, 2.01]	
Omitting Inomata et al (2020)	1.53 [1.30, 1.79]	
Omitting Inomata et al(2020)	1.67 [1.39, 2.01]	
Omitting Vehof et al (2021)	1.63 [1.33, 2.00]	100
Omitting Garcia-Marqués et al (2022)	AND SECURE AND ADDRESS OF A SECURE AND A SECURE AND ADDRESS OF A SECURE AND AD	
Omitting An et al (2022)	1.64 [1.34, 2.00]	
Omitting Bikbov et al(2022)	1.67 [1.38, 2.02]	
Omitting Cartes et al(2022)	1.62 [1.33, 1.98]	
Total (95% CI)	1.62 [1.34, 1.95]	
	(	0.5

## Sensitivity Analysis of Post-Traumatic Stress Disorder (PTSD)

Study	Odds Ratio IV, Random, 95% C	i r	Odds Ratio V, Random, 95% CI
Omitting Galor et al (2012)	1.46 [1.02, 2.07]		
Omitting Yang et al (2015)	1.43 [1.12, 1.83]		
Omitting Fernandez et al(2013)	1.43 [1.42, 1.44]		128
Omitting Vehof et al (2021)	1.45 [1.26, 1.67]		
Total (95% CI)	1.43 [1.42, 1.45]	ī	
		0.5	1

## Sensitivity Analysis of Stress

Study	Odds Ratio IV, Random, 95% CI	Odds Ratio IV, Random, 95% C	:1
Omitting Yilmaz et al(2015)	1.46 [1.15, 1.87]		
Omitting Talens-Estarelles et al (2022)			
Omitting Chung et al (2016)	1.75 [1.23, 2.48]		
Omitting Hyon et al (2019)	1.75 [1.36, 2.25]	2	3
Omitting García-Marqués et al (2022)	1.55 [1.21, 1.99]		
Omitting An et al (2022)	1.57 [1.16, 2.13]		
Total (95% CI)	1.59 [1.24, 2.05]	_	
		100-20	
		0.5	1